Theravance Biopharma (NASDAQ:TBPH) doses first healthy volunteer in Phase 1 study of TD-0903.
TD-0903 is a lung-selective, nebulized Janus kinase inhibitor (JAKi) in
development for the treatment of hospitalized patients with Acute Lung
Injury (ALI) caused by COVID-19.
The company received approval of TD-0903’s initial Clinical Trial Application (CTA) in the UK for the Phase 1 study.
The purpose of this study is to assess the safety,
tolerability and pharmacokinetics of single- and multiple-ascending
doses of TD-0903 and will enroll up to 54 volunteers.
Further program updates will be provided during Q1 financial results in early May 2020.
https://seekingalpha.com/news/3563552-dosing-underway-in-study-of-theravance-drug-for-covidminus-19
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.